Expression of a large coding sequence: Gene therapy vectors for Ataxia Telangiectasia.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 11 2023
08 11 2023
Historique:
received:
26
07
2023
accepted:
31
10
2023
medline:
9
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
epublish
Résumé
Ataxia telangiectasia is a monogenetic disorder caused by mutations in the ATM gene. Its encoded protein kinase ATM plays a fundamental role in DNA repair of double strand breaks (DSBs). Impaired function of this kinase leads to a multisystemic disorder including immunodeficiency, progressive cerebellar degeneration, radiation sensitivity, dilated blood vessels, premature aging and a predisposition to cancer. Since allogenic hematopoietic stem cell (HSC) transplantation improved disease outcome, gene therapy based on autologous HSCs is an alternative promising concept. However, due to the large cDNA of ATM (9.2 kb), efficient packaging of retroviral particles and sufficient transduction of HSCs remains challenging.We generated lentiviral, gammaretroviral and foamy viral vectors with a GFP.F2A.Atm fusion or a GFP transgene and systematically compared transduction efficiencies. Vector titers dropped with increasing transgene size, but despite their described limited packaging capacity, we were able to produce lentiviral and gammaretroviral particles. The reduction in titers could not be explained by impaired packaging of the viral genomes, but the main differences occurred after transduction. Finally, after transduction of Atm-deficient (ATM-KO) murine fibroblasts with the lentiviral vector expressing Atm, we could show the expression of ATM protein which phosphorylated its downstream substrates (pKap1 and p-p53).
Identifiants
pubmed: 37938627
doi: 10.1038/s41598-023-46332-4
pii: 10.1038/s41598-023-46332-4
pmc: PMC10632516
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19386Informations de copyright
© 2023. The Author(s).
Références
Mol Ther Methods Clin Dev. 2016 Mar 16;3:16004
pubmed: 27722179
Viruses. 2011 Jun;3(6):677-713
pubmed: 21994751
Mol Ther. 2008 Mar;16(3):534-40
pubmed: 18209733
J Virol. 2003 Nov;77(21):11324-31
pubmed: 14557618
Annu Rev Pathol. 2012;7:303-21
pubmed: 22035194
PLoS One. 2010 Jun 11;5(6):e11023
pubmed: 20552014
Adv Virus Res. 2011;81:1-31
pubmed: 22094077
N Engl J Med. 2014 Oct 9;371(15):1407-17
pubmed: 25295500
J Gen Virol. 2006 May;87(Pt 5):1339-1347
pubmed: 16603537
Mol Ther Methods Clin Dev. 2021 Apr 16;21:574-584
pubmed: 34095341
Stem Cell Reports. 2021 Jan 12;16(1):198-211
pubmed: 33186538
Mol Ther. 2006 Feb;13(2):391-400
pubmed: 16226060
J Clin Invest. 2008 Sep;118(9):3132-42
pubmed: 18688285
Cold Spring Harb Symp Quant Biol. 2005;70:99-109
pubmed: 16869743
Nature. 2015 Oct 15;526(7573):351-60
pubmed: 26469046
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Sci Rep. 2016 Jan 27;6:19750
pubmed: 26813695
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9564-8
pubmed: 7937806
Cell. 2002 Aug 23;110(4):521-9
pubmed: 12202041
J Virol. 2002 Apr;76(8):3774-83
pubmed: 11907217
Hum Gene Ther. 2007 May;18(5):423-34
pubmed: 17518616
Nat Genet. 2002 Aug;31(4):415-8
pubmed: 12134150
Nat Med. 2010 Feb;16(2):198-204
pubmed: 20098431
J Virol. 2011 Feb;85(4):1452-63
pubmed: 21106749
J Virol. 1998 Nov;72(11):8463-71
pubmed: 9765382
Orphanet J Rare Dis. 2016 Nov 25;11(1):159
pubmed: 27884168
Curr Gene Ther. 2005 Aug;5(4):387-98
pubmed: 16101513
Toxicol Appl Pharmacol. 2018 Sep 15;355:238-246
pubmed: 30006243
Cell Death Dis. 2018 Feb 22;9(3):314
pubmed: 29472706
Pediatr Allergy Immunol. 2019 May;30(3):277-288
pubmed: 30685876
Mol Biosyst. 2015 Feb;11(2):370-8
pubmed: 25353704
Front Immunol. 2019 Nov 27;10:2785
pubmed: 31849966
Mol Ther. 2016 Aug;24(7):1227-36
pubmed: 27133965
J Virol. 2001 Jul;75(13):5762-71
pubmed: 11390578
Gene Ther. 2005 Jul;12(14):1089-98
pubmed: 16003340
Science. 1995 Jun 23;268(5218):1749-53
pubmed: 7792600
J Clin Invest. 2008 Sep;118(9):3143-50
pubmed: 18688286
Leukemia. 2008 Aug;22(8):1519-28
pubmed: 18496560
Exp Hematol. 2006 May;34(5):588-92
pubmed: 16647564
Nat Rev Mol Cell Biol. 2013 Apr;14(4):197-210
pubmed: 23486281
Front Pediatr. 2019 Oct 31;7:443
pubmed: 31737588
Hum Gene Ther. 2001 Oct 10;12(15):1893-905
pubmed: 11589831
Cell. 1996 Jul 12;86(1):159-71
pubmed: 8689683
Curr Opin Genet Dev. 2017 Apr;43:120-127
pubmed: 28363112
Curr Gene Ther. 2013 Dec;13(6):453-68
pubmed: 24195603
Microbiol Rev. 1995 Sep;59(3):423-50
pubmed: 7565413
Mol Ther. 2012 Jun;20(6):1167-76
pubmed: 22472951
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142696
Front Immunol. 2018 Nov 20;9:2703
pubmed: 30515174
Anticancer Res. 2008 Jan-Feb;28(1B):401-5
pubmed: 18383876
Retrovirology. 2010 May 17;7:45
pubmed: 20478027
Sci Rep. 2017 Aug 14;7(1):8085
pubmed: 28808269
Nat Rev Genet. 2011 May;12(5):301-15
pubmed: 21445084
J Vis Exp. 2016 Jan 10;(107):
pubmed: 26779653
PLoS Pathog. 2007 May 25;3(5):e74
pubmed: 17530924
J Allergy Clin Immunol. 2011 Aug;128(2):382-9.e1
pubmed: 21665257
Front Immunol. 2018 Oct 29;9:2495
pubmed: 30420857
Virus Genes. 2017 Oct;53(5):714-722
pubmed: 28762206
Genomics. 1996 Apr 15;33(2):317-20
pubmed: 8660985
Hum Mol Genet. 1995 Nov;4(11):2025-32
pubmed: 8589678
Mol Ther. 2008 Apr;16(4):718-25
pubmed: 18334985
Nat Commun. 2016 May 27;7:11655
pubmed: 27229179
PLoS Biol. 2004 Aug;2(8):E234
pubmed: 15314653
PLoS One. 2020 Feb 13;15(2):e0228730
pubmed: 32053646
Nat Rev Genet. 2021 Apr;22(4):216-234
pubmed: 33303992